CMPS - Compass Pathways Plc logo

CMPS

Compass Pathways Plc

Rev —top 1%5Y
Hold

Compass Pathways plc develops psilocybin therapies for mental health conditions, focusing on treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa. Its lead product, COMP360, is in advanced clinical trials in the US and UK.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $463today

Score Overview

1 Year
Score
Net Growth-36.94%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-449.45%
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-4x
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Compass Pathways Plc fundamental performance

Across Compass Pathways Plc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 60M to -$ 287M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 14.22
1 Year2025-08-12
$ 4.22236.97%
5 Years2021-08-12
$ 30.74-53.74%
All Time2020-09-18
$ 29.00-50.97%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 394M$ 433M
2025$ 0.00-$ 287M$ 149M
2024$ 0.00-$ 155M$ 165M
2023$ 0.00-$ 118M$ 220M
2022$ 0.00-$ 91M$ 143M
2021$ 0.00-$ 71M$ 273M
IPO2020$ 0.00-$ 60M$ 190M

Explore beyond CMPS

You're looking at Compass Pathways Plc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies